Metabolex, Inc.
Formerly METABOLEX INC
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Sep 2013 | $30 M | No. 3 | $10 to $50 million | equity, options | SEC | |
| Nov 2009 | $6 M | No. 2 | $2 to $10 million | equity, debt, options | SEC | |
| Mar 2008 | $28 M | No. 1 | $10 to $50 million | debt, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Metabolex, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2013).
SEC Form D · Nov 2013
The industry group it chose in its notices: Biotechnology.
SEC Form D · Nov 2013
That is all the official record says: Metabolex, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: the address on record now leads to another company's site.
Investors#
No investor of Metabolex, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 335 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Charles A. McWherter, Ph. D. | Executive officer | Nov 2013 |
| Harold Van Wart, Ph. D. | Executive officer | Nov 2013 |
| Sujal A. Shah | Executive officer | Nov 2013 |
| Charles McWherter | Executive officer | Nov 2009 |
| David Karpf | Executive officer | Nov 2009 |
| Donald Hill | Executive officer | Nov 2009 |
| Harold Van Wart | Executive officer | Nov 2009 |
| Paul Quinlan | Executive officer | Nov 2009 |
| Carl G. Goldfischer, M.D. | Director | Nov 2013 |
| Edward E. Penhoet, Ph.D. | Director | Nov 2013 |
| Hari G. Kumar, Ph.D. | Director | Nov 2013 |
| Harold Van Wart, Ph. D. | Director | Nov 2013 |
| Kurt G. von Emster | Director | Nov 2013 |
| Louis G. Lange, M.D., Ph.D. | Director | Nov 2013 |
| Anthony Evnin | Director | Nov 2009 |
| Bradley Bolzon | Director | Nov 2009 |
| Carl Goldfischer | Director | Nov 2009 |
| Daan van den Noort | Director | Nov 2009 |
| Edward Penhoet | Director | Nov 2009 |
| Harold Van Wart | Director | Nov 2009 |
| Kurt Von Emster | Director | Nov 2009 |
| Louis Lange | Director | Nov 2009 |
| Robert Zerbe | Director | Nov 2009 |
About
Company in Newark, United States.